Featured Articles
-
Process Optimization And Scalability Evaluation Of Pellicon® Capsules For SPTFF Of mAb-Based Biomolecules
6/17/2022
This document describes the principles of SPTFF and how to determine operating conditions to achieve the target concentration factor with single-use Pellicon® Capsules.
-
Ultrafiltration/Diafiltration In The Antibody Drug Conjugate Manufacturing Process
6/17/2022
We review a single-use TFF device that increases operator safety, and also saves time for improved batch turnaround and flexibility in the ADC manufacturing plant.
-
Enhancing Ease Of Use Batch Turnaround And Process Flexibility With Single-Use TFF
6/17/2022
Use of single-use Pellicon® Capsules is an effective strategy for improving operational flexibility, product safety, and turnaround of a TFF step.
-
Frontiers In Digital Bioprocessing: Modular Plant Automation And Cloud
5/26/2022
As the biopharmaceutical industry is embracing digital transformation and thus evolves in its digital maturity, future-ready concepts will play a leading role in the shift toward bioprocessing 4.0.
-
Orchestration For Remote Access And Monitoring Of Bioprocess Unit Operations
5/26/2022
Digital transformation projects require a scalable connectivity solution for the manufacturing floor that is easily and rapidly deployed. Explore future-ready, flexible, deployable, and reconfigurable elements that enable connectivity among equipment.
-
One Size Does Not Fit All: Utilizing Multiple Technology Providers In Gene Therapy Manufacturing
5/19/2022
With a diverse landscape of potential partners, it is important to know what qualities to look for in a technology provider and how to traverse the challenges inherent in managing multiple relationships.
-
Bioprocessing And Scaleup Of HEK293 Cells For AAV Production
5/9/2022
MilliporeSigma has developed the VirusExpress®️ AAV Production Platform as a scalable upstream AAV production solution for viral gene therapies.
-
Viral Clearance Considerations For Adeno-Associated Virus (AAV) Viral Vectors
4/11/2022
There is no one-size-fits-all model for AAV gene therapy products when it comes to viral clearance studies. Here we address some of the questions with respect to viral clearance studies for AAV vectors.
-
Lay The Proper Foundation For Upstream Success
4/7/2022
When selecting a partner for development of upstream processes you need speed, quality and regulatory compliance – all appropriately balanced.
-
A Platform Standard For Viral Vector Manufacturing And Commercialization
4/6/2022
Learn more about platform technologies that are being developed and implemented to support large-scale production of viral vectors.